Drug Approval | August 19, 2024
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
This two-day program was attended by 40 doctors & paramedical staff
The robotic surgery program has continually pushed the boundaries of medical technology
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
India Business grew by 11.9% YoY to Rs. 1196.2 crore
The clinical trial will be conducted at 19 sites with 10,335 participants across India
Majority of organizations are looking to increase investments in public and hybrid cloud
Subscribe To Our Newsletter & Stay Updated
